# OnCo record angiogenic-switch (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/angiogenic-switch/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "angiogenic-switch" ;
  schema:name "The angiogenic switch & tumour vessels"@en ;
  schema:description "A tumour cannot grow beyond a couple of millimetres without its own blood supply. The 'switch' flips when the signals calling for new vessels (VEGF, FGF, angiopoietin) outweigh the ones holding them back (thrombospondin). The vessels that result are leaky and chaotic, which starves the tumour of oxygen, blocks drugs, and gives cancer cells a way out."@en ;
  schema:url <https://onco.cc/pathways/angiogenic-switch/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Angiogenesis> ;
  schema:citation <https://doi.org/10.1038/nrc1093> ;
  onco:tag "mechanism", "mechanics-atlas" ;
  onco:cancers <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/ovarian/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/hypoxia-activated-therapy/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/hif2a/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/csf1r/>, <https://onco.cc/targets/pdgfra/> ;
  onco:drugs <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/drugs/tivozanib/>, <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/drugs/nintedanib/>, <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/belzutifan/> ;
  onco:pathways <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/hif-vhl/>, <https://onco.cc/pathways/tumor-microenvironment/>, <https://onco.cc/pathways/intravasation-ctc-survival/> ;
  onco:terms <https://onco.cc/terms/inducing-angiogenesis/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bergers-nat-rev-cancer/> .